Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.03
Change (%) Stock is Down 2 (15.35%)
Volume1,275,783
Data as of 04/18/19 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
04/17/19Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
04/17/19Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
04/15/19Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
04/11/19Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
Upcoming EventsMore >>
DateTitle
05/08/19
through
05/09/19
Eiger BioPharmaceuticals at ChinaBio
LocationShanghai
06/04/19
through
06/07/19
Eiger BioPharmaceuticals at Jefferies Healthcare Conference
LocationNYC
06/12/19
Eiger BioPharmaceuticals at Rare Disease Innovation & Partnering Summit
LocationBoston
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.